Topics

Latest "Fitbit Schedules Q319 Financial Results November 2019" News Stories

02:22 EST 26th February 2020 | BioPortfolio

Here are the most relevant search results for "Fitbit Schedules Q319 Financial Results November 2019" found in our extensive news archives from over 250 global news sources.

More Information about Fitbit Schedules Q319 Financial Results November 2019 on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fitbit Schedules Q319 Financial Results November 2019 for you to read. Along with our medical data and news we also list Fitbit Schedules Q319 Financial Results November 2019 Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fitbit Schedules Q319 Financial Results November 2019 Companies for you to search.

Showing "Fitbit Schedules Q319 Financial Results November 2019" News Articles 1–25 of 43,000+

Wednesday 26th February 2020

Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease

− Investigational medicine TAK-062 is an oral computationally engineered super glutenase designed to improve the digestion of gluten − Successful “build to buy” relationship adds second investigational therapy to Takeda’s pipeline for the potential treatment of uncontrolled celiac disease Takeda Pharmaceutical Company Limited (


MDxHealth (R): MDxHealth Reports Financial Year 2019 Results and Provides Outlook for 2020

Conference call with Q&A today at 09:00 CET / 08:00 GMT, details provided below IRVINE, CA, and HERSTAL, BELGIUM - February 26, 2020 - MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovativ...

PCI Biotech Holding ASA: PCI Biotech's fourth quarter and preliminary 2019 results

Oslo (Norway), 26 February 2020 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim fourth quarter and preliminary 2019 results. Please find enclosed ...


bioMérieux - 2019 Financial Results

2,675 million in sales for full-year 2019, representing a reported increase of 10.5% and organic growth of 7.2% Strong sales momentum in the fourth quarter, with organic growth of 8.3% driven by s...

Tuesday 25th February 2020

IOVA Abuzz, SUPN Study Flops, IMV Plunges Despite Positive Ovarian Cancer Data

Today's Daily Dose brings you news about IMV's ovarian cancer trial results, reports of Iovance considering a possible sale, Nemaura's head -to-head study with a major Glucose Monitoring System, and disappointing trial results of Vanda and Supernus.

Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET (5:30 am PT) to discuss results from the Phase 2 trial of serlopitant in patients with chronic pruritus of unknown origin. The company’s management ...

   MDxHealth Reports Financial Year 2019 Results and Provides Outlook for 2020

Conference call with Q&A today at 09:00 CET / 08:00 GMT, details provided below IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced its financial results for the year ended December 31, 2019 and provided a business update and outlook for 2020. Michael K. McGarrity, CEO...

PCI Biotech's fourth quarter and preliminary 2019 results

Oslo (Norway), 26 February 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim fourth quarter and preliminary 2019 results. Please find enclosed the report and presentation.2019 in review - focus on execution of the pivotal RELEASE studyThe overall survival data for Phase I patients receiving the pivotal fimaChem study dose are encouragi...

Metabolic health and weight management key to minimizing diabetes risk

(The North American Menopause Society (NAMS)) Increased fat distribution during menopause has long been shown to increase insulin resistance and the risk of diabetes. A new study based on data from the Women's Health Initiative (WHI) shows that being metabolically unhealthy increases diabetes risk, even in women of normal weight. Results are published online today in Menopause, the journal of The ...

Roberts Individualized Medical Genetics Center outlines centralized genetic testing model

(Children's Hospital of Philadelphia) In a special report published today in the journal Pediatrics, Roberts Individualized Medical Genetics Center researchers, physicians, and genetic and financial counselors describe the success of the model, their plans to build on that success for the future, and the important lessons learned from their first four years in operation.

Young Adults With CRC and Gastric Cancer Have Worse Survival, Clinical Features

Amir Ali Khan, MD, discusses the results of the database analysis and the remaining questions with young adult patients with colorectal cancer and gastric cancer. 

In praise of replication studies and null results

Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that KALYDECO® (ivacaftor) will be available to eligible patients with cystic fibrosis (CF) in New Zealand from March 1. Clinicians are able to apply for patient access using the exceptional circumstances framework set up by the Pharmaceutical Management Agency (PHARMAC). “Today is an important day for the CF community in New...

Massage Equipment Market 2019-2023 | Technologically Advanced Massage Equipment to Boost Growth | Technavio

Technavio has been monitoring the massage equipment market, and it is poised to grow by USD 8.01 bn during 2019-2023, progressing at a CAGR of 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://ww...

China Xiangtai Food Co., Ltd. Entered into Business Collaboration Agreement for up to RMB35,000,000 to Expand Operation Scale and Diversify Distribution Channels

CHONGQING, China, Feb. 25, 2020 /PRNewswire/ -- China Xiangtai Food Co. Ltd. (NASDAQ: PLIN) (the "Company" or the "PLIN"), an emerging growth company primarily engaged in pork processing in China, today announced that the Company, through its primary operating subsidiary Chongqing Penglin Food Co., Ltd, entered into a business collaboration agreement (the "Agreement")...

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2019 financial results before market opens on Friday, February 28, 2020. The press release will be followed by a conference call at 8:00 a.m. ET, which will be open to the public via telephone and webcast. During the conference call,...

Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report the fourth quarter 2019 and year-end financial results on Wednesday, March 4, 2020, after the close of the US market. The announcement wil...

Alcon Reports Full Year 2019 Results

2019 net sales to third parties up 3%, or 5% constant currency (cc) Third consecutive year of top line growth Generated $920 million in cash from operations and free cash flow of $367 million Full year 2020 outlook: net sales growth of 5% to 6% (cc) and core EPS $1.95 to $2.05 Alcon (SIX: ALC) (NYSE: ALC), the global leader in eye care, reported its financial results for the full year en...

Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium®

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell, President and CEO, will host a conference call on Monday, March 16, 2020 at 8:00 a.m. ET to provide an overview of 2019 operational performance and key updates on the Company’s regulatory progress and commerci...

Tilray to Report Fourth Quarter and Full Fiscal Year 2019 Financial Results on March 2, 2020

Tilray Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced today it will report results for the fourth quarter and full fiscal year ended December 31, 2019 on Monday, March 2, 2020 after market close. The Company will host a conference call to discuss these results at 5:00 p.m. ET. Investors interes...

KORU Medical Systems Announces Record 2019 Fourth Quarter and Full Year Financial Results

Conference Call Scheduled for February 26 at 9:00 am ET Q4 2019 Highlights Net sales rose 45.7% to $6.2 million Gross margin of 63.4% Net loss narrowed to $0.1 million Adjusted EBITDA increased 47.3% to $1.1 million Full Year 2019 Highlights Net sales rose 33.5% to a record $23.2 million Gross margin increased to 64.1% Net income of $0.6 million Adjusted EBITDA increased 55...

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2019 Financial Results

Record Total Revenues Increased 14% to $2.2 Billion in 2019 2019 GAAP Diluted EPS Increased 25% to $9.09 & Adjusted Diluted EPS Increased 18% to $16.23 More than 25 Innovative R&D Programs Across ...

Neoadjuvant and Adjuvant ADT With Dose-Escalated PRT Show Similar Outcomes in Prostate Cancer

Neoadjuvant and concurrent androgen-deprivation therapy (ADT) with dose-escalated prostate radiotherapy (PRT) and concurrent and adjuvant ADT plus dose-escalated PRT were found to have no statistically significant differences in biochemical relapse-free survival in patients with localized prostate cancer, according to results of a phase III trial.

Veracyte Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Outlook

2019 Total Revenue Grew 31% to $120.4 Million; Genomic Test Volume Grew 25% to 39,612 Achieved Fourth Quarter 2019 Positive Cash Flow from Operations Fourth Quarter Acquisition Positions Company for Global Expansion Conference Call and Webcast Today at 5:00 p.m. ET

Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

- Total Revenue of $240.3 Million for the Fourth Quarter of 2019, $967.8 Million for the Full Year 2019 - - GAAP Diluted EPS of $0.22 for the Fourth Quarter of 2019, $1.02 for the Full Year 2019 - - Non-GAAP Diluted EPS of $0.26 for the Fourth Quarter of 2019, $1.16 for the Full Year 2019 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today re...


Quick Search

News Quicklinks